期刊论文

Liu, Ke;Min, Jinrong

英文

BIOCHIMICA ET BIOPHYSICA ACTA-GENE REGULATORY MECHANISMS

1874-9399

2019

1862

9

194409

10.1016/j.bbagrm.2019.194409

National Cancer InstituteUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [ACB-12002]; National Institute of General Medical SciencesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [AGM-12006]; DOE Office of ScienceUnited States Department of Energy (DOE) [DE-AC02-06CH11357]; Canada Foundation for InnovationCanada Foundation for InnovationCGIAR; Natural Sciences and Engineering Research Council of CanadaNatural Sciences and Engineering Research Council of CanadaCGIAR; University of Saskatchewan; Government of Saskatchewan; Western Economic Diversification Canada; National Research Council Canada; Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR); Howard Hughes Medical InstituteHoward Hughes Medical Institute; Department of Energy Office of Science User FacilityUnited States Department of Energy (DOE) [DE-AC02-05CH11231]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [S10OD021832]; National Institutes of Health, National Institute of General Medical SciencesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [P30 GM124169]; AbbVie [1097737]; Bayer Pharma AG [1097737]; Canada Foundation for Innovation, Eshelman Institute for InnovationCanada Foundation for Innovation [1097737]; Genome Canada through Ontario Genomics InstituteGenome Canada [1097737, OGI-055]; Innovative Medicines Initiative (EU/EFPIA) [ULTRA-DD grant] [1097737, 115766]; JanssenJohnson & Johnson USAJanssen Biotech Inc [1097737]; Merck KGaA, Darmstadt, Germany [1097737]; Boehringer IngelheimBoehringer Ingelheim [1097737]; Eshelman Institute for Innovation [1097737]; MSD [1097737]; Novartis Pharma AG [1097737]; Ontario Ministry of Research, Innovation and Science (MRIS) [1097737]; PfizerPfizer [1097737]; Sao Paulo Research Foundation-FAPESPFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [1097737]; TakedaTakeda Pharmaceutical Company Ltd [1097737]; Wellcome [1097737]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [P30GM124169, P30GM124169, P30GM124169, P30GM124169, P30GM124169, P30GM124169, P30GM124169, P30GM124169, P30GM124169, P30GM124169, P30GM124169, P30GM124169, P30GM124169, P30GM124169, P30GM124169, P30GM124169, P30GM124169, R35GM133346, P30GM124169, P30GM124169, P30GM124169] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [S10OD021832] Funding Source: NIH RePORTER

本校为第一且通讯机构

MeCP2 is an abundant protein, involved in transcriptional repression by binding to CG and non-CG methylated DNA. However, MeCP2 might also function as a transcription activator as MeCP2 is found bound to sparsely methylated promoters of actively expressed genes. Furthermore, Attachment Region Binding Protein (ARBP), the chicken ortholog of MeCP2, has been reported to bind to Matrix/scaffold attachment regions (MARs/SARs) DNA with an unmethylated 5'-CAC/GTG-3' consensus sequence. In our previous study, although we have systemically measured the binding abilities of MBDs to unmethylated CAC/GTG ...